U.S. FDA issues two observations to Cipla arm InvaGen’s U.S. facility

The U.S. Food and Drug Administration (U.S. FDA) has issued 2 observations to Cipla’s U.S. subsidiary, InvaGen Pharmaceuticals, regarding its Long Island manufacturing facility.

The observations followed a pre-approval inspection (PAI) by the regulator astatine InvaGen's manufacturing installation successful Hauppauge, Long Island, New York, from February 2 to 9.

“On decision of the inspection, InvaGen received 2 inspectional observations successful Form 483. The institution volition enactment intimately with the U.S. FDA and is committed to code these comprehensively wrong stipulated time,” Cipla said successful a filing connected Tuesday (February 10, 2026).